HI
HIK.LSE Hikma Pharmaceuticals PLC
- Market cap
- GBX 3.63B
- P/E
- 13.4x
- P/B
- 1.90x
- ROE
- 34.9%
- Dividend yield
- 3.68%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is HIK.LSE undervalued?
Graham numberHIK.LSE trades 6.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hikma Pharmaceuticals PLC fundamental analysis
No fundamental analysis for Hikma Pharmaceuticals PLC yet.
Hikma Pharmaceuticals PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and ot…
Full company profileHikma Pharmaceuticals PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hikma Pharmaceuticals PLC annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.95B | 1.94B | 2.07B | 2.21B | 2.34B | 2.55B | 2.52B | 2.88B | 3.13B | 3.35B | 6.86B |
| Gross Profit | 950M | 915M | 1.00B | 1.10B | 1.21B | 1.30B | 1.27B | 1.41B | 1.42B | 1.44B | 2.89B |
| Operating Income | 401M | 336M | 428M | 486M | 540M | 634M | 591M | 367M | 612M | 580M | 1.43B |
| EBITDA | 547M | 554M | 549M | 585M | 671M | 768M | 485M | 817M | 806M | 845M | 1.91B |
| Net Income | 155M | -843M | 282M | 486M | 431M | 421M | 188M | 190M | 359M | 402M | 885M |
| EPS | 0.66 | -3.51 | 1.17 | 2.00 | 1.81 | 1.81 | 0.84 | 0.85 | 1.61 | 1.81 | 4.05 |
| Balance Sheet | |||||||||||
| Total Assets | 4.36B | 3.39B | 3.50B | 3.93B | 4.14B | 4.37B | 4.47B | 4.68B | 5.13B | 5.67B | 5.86B |
| Total Liabilities | 1.95B | 1.86B | 1.80B | 1.80B | 1.99B | 1.91B | 2.32B | 2.47B | 2.81B | 3.07B | 3.31B |
| Shareholders' Equity | 2.40B | 1.51B | 1.69B | 2.12B | 2.14B | 2.45B | 2.14B | 2.20B | 2.31B | 2.59B | 2.54B |
| Cash & Short-term Investments | 175M | 249M | 297M | 465M | 347M | 450M | 292M | 229M | 213M | 354M | 291M |
| Total Debt | 860M | 777M | 637M | 685M | 932M | 846M | 1.28B | 1.19B | 1.31B | 1.60B | 1.97B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 293M | 443M | 430M | 472M | 464M | 638M | 530M | 608M | 564M | 367M | 670M |
| Capital Expenditure | 122M | 107M | 107M | 186M | 224M | 229M | 225M | 169M | 165M | 201M | 484M |
| Free Cash Flow | 171M | 336M | 323M | 286M | 240M | 409M | 305M | 439M | 399M | 165M | 186M |
| Ratios | |||||||||||
| ROE | 6.5% | -55.7% | 16.7% | 23.0% | 20.2% | 17.2% | 8.8% | 8.6% | 15.5% | 15.5% | 34.9% |
| ROA | 3.6% | -24.9% | 8.1% | 12.4% | 10.4% | 9.6% | 4.2% | 4.1% | 7.0% | 7.1% | 15.1% |
| Net Profit Margin | 7.9% | -43.5% | 13.6% | 22.0% | 18.4% | 16.5% | 7.5% | 6.6% | 11.5% | 12.0% | 12.9% |
| Debt to Equity | 0.36x | 0.51x | 0.38x | 0.32x | 0.44x | 0.34x | 0.60x | 0.54x | 0.57x | 0.62x | 0.78x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hikma Pharmaceuticals PLC dividends
- Dividend yield
- 3.68%
- Forward dividend
- 0.64 GBX
- Payout ratio
- 47.0%
- Ex-dividend date
- Aug 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 189M | 0.85 | 47.0% |
| 2024 | USD 175M | 0.78 | 48.7% |
| 2023 | USD 137M | 0.62 | 72.1% |
| 2022 | USD 125M | 0.56 | 66.5% |
| 2021 | USD 120M | 0.52 | 28.5% |
| 2020 | USD 109M | 0.46 | 25.3% |
| 2019 | USD 97.0M | 0.40 | 20.0% |
| 2018 | USD 84.0M | 0.35 | 29.8% |
| 2017 | USD 79.0M | 0.33 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:1 on Sep 4, 2013.
Who owns Hikma Pharmaceuticals PLC
- Insiders 32.39%
- Institutions 40.76%
- Public & others 26.86%
- Shares outstanding 207M
- Free float 146M
Hikma Pharmaceuticals PLC company profile
- Company name
- Hikma Pharmaceuticals PLC
- Ticker
- HIK.LSE
- ISIN
- GB00B0LCW083
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 9,500
- Fiscal year end
- December
- Address
- 10 Portman Square, London, United Kingdom, W1H 6AZ
- Phone
- 44 20 7399 2760
- Website
- hikma.com
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.
Hikma Pharmaceuticals PLC management
10- H.E Said DarwazahChief Executive Officer · born 1957
- Mr. Mazen Samih Taleb DarwazehExecutive Vice Chairman & Deputy CEO of MENA · born 1958
- Mr. Khalid Walid Hussni Al Nabilsi CPADeputy CEO of North America and Europe & Director · born 1972
- Mr. Areb AL KURDIVP, Group Financial Controller & Acting CFO · born 1974
- Ms. Patricia BousfieldChief Information Officer
- Mr. Guy FeatherstoneAssociate Director of Investor Relations
- Mr. Samuel ParkGeneral Counsel
- Mr. Bassam Wael Rushdi Kanaan CFA, CPAExecutive Vice President of Corporate Development and M&A · born 1965
- Mr. Hussein Omar ArkhaghaChief People Officer
- Ms. Susan RingdalExecutive Vice President of Strategic Planning & Global Affairs